Skip to main content

Table 6 Stability profile of lyophilized HVD-NLCs (VER-9) in terms of PS, PDI, ZP, and drug content (n = 3) in different storage conditions

From: Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation

Stability parameters 0 month 1 month 3 month 6 month
Storage condition (5 ± 3 °C)
 PS (nm) 193.76 ± 2.10 191 ± 3.17 192.46 ± 4.36 198.43 ± 2.90
 PDI 0.542 ± 0.075 0.556 ± 0.052 0.554 ± 0.321 0.525 ± 0.251
 ZP (mV) − 48.5 ± 1.31 − 45.3 ± 2.55 − 42 ± 2.65 − 46.11 ± 3.11
 Drug content (%EE) 100.03 ± 0.03 99.53 ± 0.72 99.06 ± 1.23 98.46 ± 1.67
Storage condition (25 ± 2 °C/60 ± 5%RH)
 PS (nm) 193.76 ± 2.10 962.16 ± 12.36 NM NM
 PDI 0.542 ± 0.075 1 NM NM
 ZP (mV) − 48.5 ± 1.31 − 46.25 ± 2.36 NM NM
 Drug content (%EE) 100.03 ± 0.03 92.69 ± 0.75 87.56 ± 1.26 82.14 ± 1.90
Storage condition (40 ± 2 °C/75 ± 5% RH)
 PS (nm) 193.76 ± 2.10 865.12 ± 15.26 NM NM
 PDI 0.542 ± 0.075 0.963 ± 0.056 NM NM
 ZP (mV) − 48.5 ± 1.31 − 49.47 ± 2.45 NM NM
 Drug content (%EE) 100.03 ± 0.03 91.78 ± 0.44 68.24 ± 1.80 65.84 ± 7.88
  1. NM not measurable, PS particle size, PDI polydispersity index, ZP Zeta potential